Introduction
Antibody drug conjugates (ADC) have emerged as a promising new class of cancer therapeutics.
High-throughput screening technologies have enabled the identification of highly specific targets that serve as selective entry points for antibodies appended with extremely potent cytotoxic agents. Numerous antibody drug conjugates are now in various stages of clinical development and one was recently granted accelerated approval based on profound responses achieved in CD30-positive lymphomas (1) (2) (3) . To some extent, the criteria for applying an ADC approach in cancer is simplified by the use of drugs that kill cells by generalized mechanisms rather than relying upon specific genetic attributes of the target. Therefore, there is an opportunity for ADC therapy to serve as a more tolerable, more effective alternative to standard of care chemotherapy, which is frequently used in combination with targeted treatments.
Expression of EDNRB is highly restricted in normal adult tissues and is overexpressed in the majority of metastatic melanomas (4, 5) . We have recently described an anti-endothelin B receptor (EDNRB) ADC comprised of a humanized monoclonal antibody conjugated to monomethylauristain E (MMAE) that is efficacious in mouse xenograft models of human melanoma (5) . Upon binding to cells, the antibody is rapidly internalized and the released drug disrupts cell proliferation by interfering with microtubule dynamics. The ADC has demonstrated efficacy in human melanoma xenograft models expressing amounts of cell-surface EDNRB comparable to that in the patient population. In both rodent and primate models the anti-EDNRB ADC exhibits favorable pharmacokinetic properties and is well tolerated at exposures predicted to be efficacious based on tumor xenograft studies (unpublished observation, JA, PP).
Metastatic melanoma is a highly aggressive cancer with a 5-year survival rate of less than 10% and median survival of less than 8 months (6) (7) (8) . The incidence of melanoma has increased over the past few decades and the annual mortality rate has surpassed 9000 in North America. Standard of care treatment for metastatic melanoma includes administration of the alkylating agent dacarbazine and the cytokine Interleukin-2 (9) . However, the response rate to these therapies is very low and durable responses are rare. More recently, a number of innovative therapies targeting the MAPK pathway have produced significant responses in advanced metastatic disease (10, 11) . In particular, vemurafenib, an FDA approved small molecule inhibitor of BRAF, has demonstrated increased overall survival in the treatment of metastatic melanoma containing activating BRAF mutations (12, 13) . Additional compounds targeting BRAF, as well as MEK, which resides immediately downstream of BRAF, are also under development (14) (15) (16) (17) . The incidence of BRAF mutations in metastatic melanoma is approximately 50% with an additional 15% harboring NRAS mutations (18) . Thus, the majority of melanoma patients will qualify diagnostically for treatment with these agents.
Because of the importance of MAPK pathway inhibition in the treatment of melanoma, combination therapy has the potential to provide improved outcomes, and is likely to become standard of care. However, it is beneficial to establish a biological or pharmacological rationale for combination strategies in advance. Considering the emergence of MAPK pathway inhibitors and their anticipated widespread adoption in the treatment of melanoma, we assessed their impact on 5 the expression levels of EDNRB and the efficacy of the corresponding ADC in the preclinical setting.
Using melanoma cell lines and tumor xenografts, we examined several scenarios under which the drugs might influence the activity of the anti-EDNRB ADC: mutant BRAF, responsive to BRAF inhibition; mutant BRAF, intrinsically resistant to BRAF inhibition; wildtype BRAF and NRAS ; and wildtype BRAF and mutant NRAS. Finally, we examined mutant BRAF cells adapted in long-term culture to resist BRAF inhibition. Under all scenarios described, MAPK pathway inhibitors elevate the levels of EDNRB on melanoma cells and thereby improve the efficacy of the ADC. distribution to end users. Cells were used for less than 6 months after distribution. Cells were cultured in appropriate media at 370C and 5% CO 2 To develop cell lines resistant to BRAF inhibitor PLX4032, V600E BRAF cell lines 928 mel, UACC-257X2.2 and V600D BRAF cell line WM-266-4 were grown in culture media containing step-wise increasing concentrations of PLX4032 over a period of 10-12 weeks to obtain a sub-population of these cells that were viable in relatively high concentrations of the inhibitor. PLX4032 resistant lines, 928 mel and UACC-257X2.2 could be maintained in culture media containing 2 μM PLX4032 whereas PLX4032-resistant WM-266-4 cell line could be maintained in culture media containing 1 μM PLX4032.
To study the effects of signaling pathway inhibitors on melanoma cells, 2 x 10 6 cells were plated on 4-well dishes and treated overnight with various inhibitors at the indicated concentrations. To study the MAPK phosphorylation status of cell lines rendered step-wise resistant to BRAF inhibitor PLX4032, parental and PLX4032 resistant lines were serum starved overnight on 60 mm dishes, in the presence of 10 μM BRAF inhibitor PLX4032 as indicated. Cells from the experiments described above, were harvested, either live for Flow Cytometry or into a 1% n-Dodecyl β-D-maltoside (DDM)
containing lysis buffer to prepare lysates for further analysis by immunoblotting.
To assess the effects of PLX4032 on cell viability, cells were plated at 1,500 per well in 50 μL of normal growth medium in 96-well clear-bottom plates. Twenty-four hours later, an additional 50 μL of culture medium with serial dilutions of PLX4032 or controls was added to triplicate wells. Five days later, cell survival was determined using CellTiter-Glo Luminescent Cell Viability Reagent (G7572; Promega Corporation) and with an EnVision 2101 Mutilabel Reader (Perkin-Elmer).
Transcript analysis-mRNA transcript analysis were performed in triplicate on a 7500 Real Time PCR thermal cycler, Applied Biosystems (ABI) using ABI reagents. Either FAM-TAMRA or FAM-BHQ fluorophore labeled probes were used with flanking primers for the detection of various genes.
Primer and probe sets were designed as follows: 1996) . Antibodies were conjugated with monomethyl auristatin E (MMAE) as described previously (22) . The drug to antibody ratio for 5E9-vc-MMAE was 3.5 and the drug to antibody ratio for control IgG-vc-MMAE was 3.3. Six to eight-week-old female mice (unless 
Results
Several studies have demonstrated that the expression of melanocyte lineage markers, such as tyrosinase, MITF, PMEL17 and EDNRB, are suppressed by MAPK signaling (23) (24) (25) (26) . Since the expression level of a cell-surface target can affect the efficacy of an ADC, we evaluated the suitability of combining the anti-EDNRB ADC with the BRAF inhibitors PLX4032 (27) and G590945; and two chemically distinct MEK inhibitors, GDC-0973 and GDC-0623. We started with the COLO 829 human melanoma model, which contains a V600E BRAF mutation and is responsive to MAPK pathway inhibition. Treatment of the COLO 829 melanoma cell line with PLX4032, as well as with the MEK inhibitors GDC-0623 and GDC-0973, resulted in a dramatic increase in levels of total and cell surface EDNRB protein ( Fig. 1A and B) . The MAPK pathway inhibitors also produced an increase in EDNRB mRNA transcript, consistent with gene activation as the basis for increased EDNRB protein (Fig. 1C ). Additional melanoma cell lines SK-MEL-5, 928mel, UACC-257 and WM-266-4, all with V600 BRAF mutations, and 537mel, which is wildtype for BRAF, all underwent increased EDNRB protein and mRNA in response to MEK inhibitors GDC-0973 and GDC-0623 and BRAF inhibitor G590945 (Suppl. Fig S1 A-F) . Data analysis for all in vivo efficacy studies is detailed in Suppl. Tables S1 and S2 and methods used for determining tumor growth inhibition is described in Supplementary Materials and Methods.
To assess the impact of BRAF inhibition on EDNRB expression in vivo, we established COLO 829 tumor xenografts in mice. PLX4032 was administered at a dose of 10 or 30 mg/kg twice per day for mRNA by RT-PCR revealed a comparable increase in EDNRB mRNA levels in animals treated with either dose level of PLX4032 relative to vehicle (Fig. 1D) . Inhibition of the MAPK pathway was confirmed by immunoblotting for phosphorylated ERK in tumor lysates (Fig. 1E) . The impact of PLX4032 on the levels of EDNRB in the COLO 829 tumor xenografts prompted us to evaluate this combination in an efficacy study. To specifically examine an interaction of the two drugs, we examined dose responses with either agent alone and then intentionally selected doses that would not produce complete responses as single agents. We administered a single sub-optimal dose of the anti-EDNRB ADC alone, which produced a modest retardation in tumor growth, whereas PLX4032 alone, dosed twice a day at 30 mg/kg for 21 days, resulted in an approximate 50% inhibition (Fig. 1F) . However, combining the two agents at these same doses resulted in complete tumor stasis for the treatment period. To rule out a possible impact of the PLX4032 on clearance of the ADC, we measured ADC blood levels and observed comparable exposure in the presence or absence of PLX4032 (Suppl. Fig. S2 ). We also tested the combination of a BRAF inhibitor distinct from PLX4032, G590945 (21) , and the ADC at varying doses in UACC-257X2.2, a second model of melanoma harboring mutant BRAF. At all dose levels examined, the combination of drugs produced better responses than either alone (Suppl. Fig. S3 ).
While the anti-EDNRB ADC and PLX4032 combine favorably in the COLO 829 and UACC-257X2.2 tumor efficacy models, this could result from additive independent effects not attributable to any specific facilitation of the ADC by the BRAF kinase inhibitor. To explore this further we tested the A2058 melanoma model, which harbors a V600E BRAF mutation but is intrinsically refractory to MAPK pathway inhibitors (Suppl. ( Fig. 2A and B) . As expected, administration of 10 mg/kg of PLX4032 twice daily for 21 days did not significantly inhibit tumor xenograft growth (Fig. 2C) . Nevertheless, this dose of PLX4032 further enhanced the efficacy observed with a single 6 mg/kg dose of anti-ENDRB ADC (Fig. 2C) . Increasing the dose of PLX4032 to 30 mg/kg still did not yield significant tumor growth inhibition, nor did it facilitate the activity of the ADC beyond that observed in combination with 10 mg/kg PLX4032.
We next tested the MEK inhibitor GDC-0973 with the A2058 model, which elicited a stronger induction of EDNRB and a more pronounced inhibition of phosphorylated ERK relative to PLX4032 ( Fig. 2D and E). Administration of 5 or 10 mg/kg of GDC-0973 for 3 days to animals bearing A2058 tumors resulted in an induction of EDNRB transcript (Fig. 2F) . However, no anti-tumor activity was observed with the A2058 model when animals were administered the maximum tolerated dose of 7.5 mg/kg GDC-0973 over a 21-day period (Fig. 2G) . Although ineffective as a single agent, GDC-0973 strongly enhanced the activity of the anti-ENDRB ADC (Fig. 2G) . Administration of a negative control ADC that does not recognize A2058 cells, exhibited no activity either alone or in combination with GDC-0973 (Fig. 2G, inset) . Thus in this particular example the effect of combining the MAPK pathway inhibitor with the ADC cannot simply be additive, and argues for a mechanistic interaction between the two agents. Moreover, these data imply that MAPK pathway inhibitors could have utility in melanoma patients that exhibit intrinsic resistance to these drugs as single agents.
The clinical application of PLX4032 is reserved for melanoma patients with tumors containing detectable BRAF V600 mutations (27, 28) . This accounts for approximately 50% of melanomas, while another 15% are mutant for NRAS, with the remainder wildtype for both BRAF and NRAS Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. (18) . To represent the latter category, we implemented the SK23-mel model, which contains both wildtype BRAF and NRAS. As anticipated, PLX4032 produced limited inhibition of ERK phosphorylation and a modest increase in EDNRB protein as detected by immunoblotting and no increase in cell-surface EDNRB was detected by flow cytometry (Fig. 3A and B) . By contrast, the MEK inhibitor GDC-0973 elicited dramatic effects on both ERK phosphorylation and EDNRB expression ( Fig. 3A and B) .
Dosing of mice bearing SK23-mel tumor xenografts either once with 6 mg/kg of the anti-EDNRB ADC or daily with 7.5 mg /kg of GDC-0973 significantly inhibited tumor growth (Fig. 3C ).
Nevertheless, combining the agents at these doses was more efficacious than either agent alone.
Anti-tumor activity was no longer apparent when the ADC was dosed singly at 3 mg/kg, and activity with GDC-0973 alone was reduced when the dose was lowered to 3 mg/kg. However, when the drugs were combined at these doses, marked tumor inhibition was restored. These data suggest that MEK inhibition would augment the efficacy of the anti-EDNRB ADC in melanoma with wildtype BRAF and NRAS.
Finally, we examined the melanoma cell line IPC-298 that harbors mutant NRAS and wildtype BRAF. 
phosphorylation of ERK and decreased the expression of EDNRB (Fig. 4A and B) . By contrast, MEK inhibition effectively inhibited the MAPK pathway in the IPC-298 cell line, resulting in a concomitant increase in the expression of EDNRB. These results are consistent with the repression of EDNRB by MAPK signaling.
Although it is apparent that the MEK inhibitor augments the efficacy of the ADC, this affect might require a specific dosing schedule in order to maximally exploit the benefit of EDNRB induction by the inhibitor. To examine this, EDNRB transcript and the inhibition of MAPK pathway was assessed in a time course experiment. Mice bearing SK23-mel tumor xenografts were dosed once a day with either 7.5 mg/kg of the MEK inhibitor GDC-0973 or the corresponding vehicle control for a period up to 21 days, initiated on day 0. Tumors were harvested from each group on day 1, 3, 7, 14, 21 and 28, where day 28 represents a 7-day wash out period for the drug. Maximal EDNRB induction was maintained between days 3-7, decreasing gradually thereafter with recovery to near basal levels following the washout at day 28 (Suppl. Fig. 5A ). These results point to a broad scheduling window of opportunity for administrating the ADC with respect to that of the MEK inhibitor.
Moreover, the induction of EDNRB is already apparent at Day 1, in both the SK23-mel and COLO 829 tumor models, suggesting that the drugs could be initiated simultaneously (Suppl. Fig 5A and   B) .
Melanomas can acquire resistance to BRAF inhibition through a variety of reported mechanisms (29, (33) (34) (35) (36) . To determine whether EDNRB remains elevated following acquired resistance to PLX4032, resistant melanoma cell lines containing V600E BRAF were derived with prolonged Following chronic exposure to increasing concentrations of PLX4032, the 928mel and UACC-257X2.2 derivatives were no longer inhibited by concentrations as high as 2 μM PLX4032 and WM-266-4 was resistant up to 1μM. Analysis of cell surface levels of EDNRB by flow cytometry revealed that all three PLX4032-resistant derivatives retained elevated expression of EDNRB relative to their corresponding parental lines (Fig. 5A) . The WM-266-4 and 928 mel drug-resistant derivatives both exhibited lower basal levels of phosphorylated ERK, consistent with a resistance mechanism involving reduced reliance upon MAPK signaling (Fig. 5B) . By contrast, the UACC-257X2.2 resistant derivative maintained phosphorylated ERK levels comparable to the parental cell line. However, addition of PLX4032 still resulted in diminution of MAPK signaling as determined by phosphorylated ERK. The UACC-257X2.2 derivative also underwent a further increase in EDNRB upon addition of the MEK inhibitor GDC-0973 (Fig. 5C ). Our data indicate that the level of EDNRB is elevated in response to MAPK inhibition and thereby enhances the efficacy of the ADC directed against it. However, increased on-target toxicity might be expected should a comparable enhancement occur in normal tissues. The ADC used in our studies cross reacts with mouse EDNRB, yet no overt signs of enhanced toxicity were observed when combined with MAPK inhibitors (unpublished observation). Nevertheless, we compared the expression of the EDNRB mRNA transcript in the normal tissue of animals administered vehicle control and MAPK inhibitors. Low levels of EDNRB mRNA transcript were detected by RT-PCR in a variety of normal mouse tissues overall, and no significant relative increases were noted in response to inhibitors of either MEK or BRAF (Fig. 6 A and B measurements for MEKi administration were performed in SKmel-23 tumor bearing animals where the increase in EDNRB mRNA is readily apparent in the tumor material from these animals (Fig. 6B) .
We also examined cultured adult normal human epidermal melanocytes, which express detectable cell surface levels of EDNRB. Incubation with the BRAF inhibitor did not increase EDNRB cellsurface expression, consistent with the specificity of this drug for cells containing mutant BRAF (Fig.   6C ). However, an increased level of cell surface EDNRB was observed in normal melanocytes in response to the MEK inhibitor. Based on the relative insensitivity of normal melanocytes to ADCs containing MMAE, likely attributable to their slow doubling time, the potential for toxicity in normal skin would be expected to be limited (37) .
To determine the mechanism of cell death, we performed caspase activation assays on melanoma cell lines exposed to MAPK pathway inhibitors, the ADC or the combination. As expected, the raf inhibitor PLX4032 had no effect on caspase 3/7 activation in the BRAF wildtype SK23mel cell line nor did its presence add to the caspase 3/7 activation observed with the ADC alone (suppl . Fig 6 B,   C) . By contrast, addition of the MEK inhibitor, which was ineffective alone, resulted in an approximate 7-fold increase in caspase activation relative to that observed with ADC. In the A2058 and colo829 cells, Caspase 3/7 activation was detected upon inhibition of MEK or BRAF and, when combined with the ADC, the signal appeared additive to that observed with the ADC alone. An assessment of early and late apoptosis, using Annexin V and propidium iodide staining, yielded results consistent with Caspase 3/7 (suppl. Fig. 6 B,C) . 
Discussion
It has been appreciated for many decades that the use of drugs in combination can confer enhanced benefit to cancer patients (38) . Combining drugs of various modalities, such as antimetabolites, DNA damaging agents and microtubule disrupting agents, combats the diversity inherent to cancer and diminishes the likelihood of drug resistance. Even modern therapies targeting defined genetic attributes of a cancer are foiled by second site mutations or mechanistic redundancies that result in drug resistance and relapse (39) (40) (41) . Thus, combining rational therapies in a mechanistically oriented manner will be instrumental in overcoming intrinsic and acquired drug resistance in cancer therapy. In particular, understanding and exploiting the mechanisms by which cancer cells compensate for or respond to targeted therapies will facilitate development of new Nevertheless, the presence of a V600 mutation does not guarantee a response to either BRAF or MEK inhibition, as some of these melanomas appear intrinsically resistant to the drugs. However, in some resistant cells, such as the A2058 in our study, inhibition of phosphorylated ERK and upregulation of EDNRB still occurs in response to MAPK pathway inhibition, resulting in a more favorable response to the anti-EDNRB ADC. This is consistent with a previous study in which a number of melanoma cell lines resistant to PLX4032, up-regulated the expression of melanocytespecific markers in response to the drug (23) . This same study used gene expression signatures to define a category of melanoma cell lines that maintained high levels of melanocytic antigens, relative to those with low levels. However, cell lines with low levels underwent increased expression of the antigens in response to PLX4032. This was also evident for EDNRB in our study, and suggests that the level of the receptor on naïve melanoma cells might not be a suitable any specific mutational status, appears to be the key diagnostic marker for combining the ADC with MAPK inhibitors. That the vast majority of melanomas are addicted to MAPK signaling, suggests that a broad melanoma patient population might benefit from the combination. Acquired resistance to BRAF inhibition has been observed in melanoma patients who relapse following prolonged administration of PLX4032 (19, 49) . Acquired resistance can also be recapitulated in vitro and a variety of mechanisms that account for it have been described (29, (33) (34) (35) (36) . Most of these resistance mechanisms involve the maintenance of MAPK signaling through the circumvention of BRAF, as evidenced by ERK phosphorylation. In other cases, phosphorylated ERK is still reduced by BRAF inhibition, yet the cells remain viable, indicating a diminished reliance upon 
MAPK signaling (34) . We generated clones resistant to PLX4032 from three independent melanoma cell lines, one of which appeared to maintain elevated phospho-ERK, whereas the other two exhibited lowered levels. Nevertheless, all three resistant lines retained elevated levels of EDNRB relative to the corresponding parental cells. Thus despite potential differences in the manner by which the melanoma cells might resist MAPK pathway inhibition, the elevated expression of EDNRB remained intact.
Scheduling the dosing of a therapeutic regimen that relies upon an interaction between two drugs might require specific timing to ensure an efficient interaction. The anti-EDNRB ADC attains maximum blood exposures levels shortly after administration but clears slowly with a half-life on the order of 9 days in rodents and non-human primates (unpublished data). Our results show the EDNRB remains elevated throughout the 21-day course of daily dosing with a MEK inhibitor. Thus the two drugs should have ample opportunity to interact, precluding a need for precise dose scheduling. Nevertheless, our data show that maximal elevation of EDNRB levels by the MEK inhibitor was reached within 1-3 days of administration and could therefore have implications for achieving an optimal combinatorial effect.
One potential outcome related to safety is the increased expression of EDNRB on normal melanocytes in response MAPK inhibition. Although this did not occur in response to BRAFi, we did observe upregulation of cell-surface EDNRB by MEK inhibitors. Thus, the potential loss of normal melanocytes targeted by the ADC could be exacerbated in the presence of MEK inhibition. This could affect pigmentation in hair or skin, possibly manifested as vitiligo-like symptoms. Although clearly undesirable, such outcomes ought to be readily monitorable and manageable in the clinic. 
Despite the increase of EDNRB on normal melanocytes, we believe the affect of the ADC will be milder than that on melanoma cells due to the anti-mitotic nature of MMAE. In a separate study targeting PMEL17 in melanoma we have reported that the impact of anti-PMEL17vcMMAE on the viability of normal melanocytes is substantially tempered relative to that on melanoma cells (36) .
Overall, our study shows that inhibition of MAPK signaling potentiates the efficacy of the anti-EDNRB ADC irrespective of the mutational background or response of a melanoma to MAPK pathway inhibition alone. The data further supports the retention of elevated EDNRB expression on melanoma cells, despite prolonged exposure and acquired resistance to a BRAF inhibitor.
Combining the anti-EDNRB ADC with MAPK pathway inhibitors could provide enhanced benefit to wide range of melanoma patients. 
